Research Topics
Genomes and Genes | Timothy P HughesSummaryAffiliation: South Australia Country: Australia Publications
| Collaborators
|
Detail Information
Publications
Measuring minimal residual disease in chronic myeloid leukemia: fluorescence in situ hybridization and polymerase chain reactionTimothy P Hughes
Division of Haematology, Institute of Medical and Veterinary Science, Adelaide 5000, South Australia, Australia
Clin Lymphoma Myeloma 9:S266-71. 2009....
Dasatinib alters the metastatic phenotype of B16-OVA melanoma in vivoCara K Fraser
Hanson Institute, Adelaide, The University of South Australia, South Australia, Australia
Cancer Biol Ther 10:715-27. 2010....- Dasatinib inhibits the secretion of TNF-alpha following TLR stimulation in vitro and in vivoCara K Fraser
Hanson Institute, South Australia, Australia
Exp Hematol 37:1435-44. 2009..The purpose of this study was to evaluate the effect of dasatinib on cytokine secretion in response to toll-like receptor (TLR) stimulation... - The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34+ cellsJane R Engler
Division of Haematology, SA Pathology RAH Campus, Adelaide, Australia
Blood 116:2776-8. 2010..Therefore kinase inhibition in these mature cells, and not the CD34(+) cells, may be the key determinant of response in CML... - Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients?Stephen Fitter
Myeloma Research Laboratory, Department of Hematology, Centre for Cancer Biology, Institute of Medical and Veterinary Science, G P O Box 14, Adelaide, South Australia 5000, Australia
J Clin Endocrinol Metab 95:3763-7. 2010..The mechanism(s) by which imatinib improves glycemic control in chronic myeloid leukemia (CML) patients with type 2 diabetes remains unclear... - Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapyTimothy P Hughes
Institute of Medical and Veterinary Science, Adelaide, Australia
Blood 112:3965-73. 2008..Superior responses achieved in patients able to tolerate imatinib at 600 mg suggests that early dose intensity may be critical to optimize response in CP-CML. The trial was registered at www.ANZCTR.org.au as #ACTRN12607000614493... - Drug-interaction studies evaluating T-cell proliferation reveal distinct activity of dasatinib and imatinib in combination with cyclosporine AStephen J Blake
Department of Haematology, SA Pathology, RAH Campus, Adelaide, South Australia, Australia
Exp Hematol 40:612-21.e6. 2012..Furthermore, the technique to evaluate drug interactions is novel, and applicable to study any interaction affecting proliferation... - Inhibition of c-fms by imatinib: expanding the spectrum of treatmentAndrea L Dewar
Division of Haematology, Hanson Institute, Institute of Medical and Veterinary Science, Adelaide, South Australia
Cell Cycle 4:851-3. 2005..We also speculate that imatinib may be used in diseases where bone destruction occurs due to excessive osteoclast activity, such as in the haematologic malignancy, multiple myeloma... - Dysregulation of bone remodeling by imatinib mesylateKate Vandyke
Myeloma and Mesenchymal Research Laboratory, Division of Haematology, Centre for Cancer Biology, Hanson Institute, Institute of Medical and Veterinary Science, Adelaide, Australia
Blood 115:766-74. 2010..The potential application of imatinib in the treatment of cancer-induced osteolysis will also be discussed... - Imatinib inhibits the functional capacity of cultured human monocytesAndrea L Dewar
Division of Haematology, Hanson Institute, Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia
Immunol Cell Biol 83:48-56. 2005.... - Imatinib as a potential antiresorptive therapy for bone diseaseAndrea L Dewar
Division of Haematology, Institute of Medical and Veterinary Science, Frome Rd, Adelaide 5000, Australia
Blood 107:4334-7. 2006..These results suggest that imatinib may have therapeutic value as an antiosteolytic agent in diseases such as osteoporosis, metastatic bone disease, and multiple myeloma... - Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivoCara K Fraser
Experimental Therapeutics Laboratory, Hanson Institute, South Australia, Australia
Exp Hematol 37:256-65. 2009..The purpose of this study was to evaluate the inhibitory action of dasatinib on antigen-specific CD8(+) and CD4(+) T-cell function, as well as natural killer (NK) cell cytotoxicity... - Mutational analysis in chronic myeloid leukemia: when and what to do?Susan Branford
Department of Molecular Pathology, SA Pathology, University of Adelaide, Adelaide, South Australia, Australia
Curr Opin Hematol 18:111-6. 2011..More sensitive mutation techniques that focus on the detection of a limited number of specific mutations may be beneficial, but are yet to prove their clinical utility for the early detection of relapse in routine practice... - Reverse transcription with random pentadecamer primers improves the detection limit of a quantitative PCR assay for BCR-ABL transcripts in chronic myeloid leukemia: implications for defining sensitivity in minimal residual diseaseDavid M Ross
Division of Haematology, Institute of Medical and Veterinary Science, Adelaide, Australia
Clin Chem 54:1568-71. 2008..More sensitive PCR methods are required to assess whether these patients have a long-term continuing decline in residual disease... - Dual transcription of b2a2 and b3a2 BCR-ABL transcripts in chronic myeloid leukaemia is confined to patients with a linked polymorphism within the BCR geneSusan Branford
Division of Molecular Pathology, Institute of Medical and Veterinary Science, Box 14, Rundle Mall, Adelaide, SA 5000, Australia
Br J Haematol 117:875-7. 2002..We conclude that the BCR intronic polymorphism is associated with activation of a cryptic branchpoint resulting in reduced efficiency of RNA splicing and exon 14 (b3) skipping in BCR and BCR-ABL... - Strategies for the treatment of imatinib-resistant chronic myeloid leukemiaChi hung Hui
Hematology Division, Hanson Institute, Institute of Medical and Veterinary Science, Frome Road, Adelaide SA 5000, Australia
Clin Adv Hematol Oncol 1:538-45, 559. 2003..The useful laboratory tests to study imatinib resistance and a current Australian CML study employing imatinib dose intensification and sequential combination therapy for newly diagnosed patients are also outlined... - How complete is "complete" molecular response in imatinib-treated chronic myeloid leukemia?David M Ross
Division of Haematology, Institute of Medical and Veterinary Science, Adelaide, SA, Australia
Leuk Lymphoma 49:1230-1. 2008 - Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implicationsDevendra K Hiwase
Division of Haematology, Institute of Medical and Veterinary Science, University of Adelaide, Adelaide, South Australia, Australia
Clin Cancer Res 14:3881-8. 2008..The relevance of OCT-1 activity and efflux pumps in determining intracellular uptake and retention (IUR) of dasatinib was assessed... - Predicting the response of CML patients to tyrosine kinase inhibitor therapyDeborah L White
Division of Haematology, SA Pathology IMVS RAH Campus, Frome Road, Adelaide, South Australia, Australia
Curr Hematol Malig Rep 4:59-65. 2009..In the future, assays that directly assess the efficacy of the protein-drug interaction, taking into account factors intrinsic to the patient and the amount of drug freely available in the plasma, are likely to be of greater value... - Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinibAndrea L Dewar
Division of Haematology, Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia
Blood 105:3127-32. 2005..Imatinib should now be assessed for activity in diseases where c-fms activation is implicated, including breast and ovarian cancer and inflammatory conditions... - High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistanceSusan Branford
Institute of Medical and Veterinary Science, Adelaide, Australia
Blood 99:3472-5. 2002..Certain mutations may respond to higher doses of imatinib, whereas other mutations may mandate switching to another therapeutic strategy... - Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2Laura N Eadie
Division of Hematology, SA Pathology, Adelaide, South Australia, Australia
Leuk Lymphoma 54:569-78. 2013..Imatinib and nilotinib appear to be transported by ABCB1 but do not interact strongly with ABCG2. Furthermore, ABCB1 efflux of nilotinib may be concentration-dependent with transport occurring at clinically relevant concentrations... - Autologous stem cell collection and autograft for patients with chronic myeloid leukemia in the era of ABL kinase inhibitors: back to the benchChi-hung Hui
Haematology Division, Hanson Institute, Institute of Medical and Veterinary Science, Adelaide, SA 5000, Australia
Leuk Lymphoma 47:1721-3. 2006